Dubai-based alternative investment group Evolvence Capital has invested Dh19.2 million in the Indian pharmaceutical firm Anjan Drugs and plans two to three more investments worth more than $100m (Dh367m) in the coming months, said CEO Khaled Al Muhairy. "We are targeting companies that export from India to the US," said Muhairy.
"We are investing with a long-term perspective. India will attract a lot of pharmaceutical research as costs are significantly low compared to the West," Al Muhairy told Emirates Business.